Good morning and welcome to Thanksgiving week! STAT reporter Andrew Joseph right here filling in for Mr. Pharmalot immediately. It’s my first Thanksgiving since shifting over to London to increase STAT’s European protection, however by no means concern, a Thanksgiving feast will likely be had on Thursday. (A reminder: It’s not too early to get began on some prep. I made my pie crusts over the weekend and they’re going to hold within the freezer for a couple of days. Additionally, have you ever thought-about how lengthy it takes to thaw your turkey?) Wishing these of you celebrating this week, wherever you might be, a cheerful vacation, and even when the large day comes round however every year, it by no means hurts to remind your self what it’s you’re grateful for. Cheers!
4 CRISPR pioneers mirror in STAT on the approval of the world’s first CRISPR-based drugs and on the way forward for gene-editing therapies. Simply over a decade after their first CRISPR papers have been revealed, Jennifer Doudna, Emmanuelle Charpentier, Feng Zhang, and George Church all chime in concerning the authorization of Casgevy within the U.Okay. for sickle cell and beta thalassemia. Additionally they focus on the divergent paths they’ve taken over the previous 10 years, the promise of gene enhancing, and the challenges that CRISPR should clear sooner or later.
The U.Okay. and the pharmaceutical trade have reached a deal on a five-year plan outlining how the well being system pays for medication, because the nation tries to maintain a lid on its medicines spending whereas concurrently build up its life sciences trade, STAT writes. The present plan, which has drawn the ire of pharma firms, requires drug firms to pay rebates again to the U.Okay. if spending on medicines will increase by greater than 2% a yr. Beneath the brand new settlement, the extent of allowed development in drug gross sales will improve from 2% in 2024 to 4% by 2027.